{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:23:44Z","timestamp":1780514624765,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.100891","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T15:54:36Z","timestamp":1769874876000},"page":"100891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of Celiac Disease After Immunotherapy: A Case Series"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-5213","authenticated-orcid":false,"given":"Alyyah","family":"Malick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Lagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneeta","family":"Krishnareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib1","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"issue":"7","key":"10.1016\/j.gastha.2026.100891_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/MCG.0000000000001705","article-title":"Immunotherapy-induced colitis: a comprehensive review of epidemiology, clinical presentation, diagnostic workup, and management plan","volume":"56","author":"Vaziri","year":"2022","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"10.1016\/j.gastha.2026.100891_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/CJI.0000000000000383","article-title":"Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies","volume":"44","author":"Tran","year":"2021","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.gastha.2026.100891_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2019-0083","article-title":"Diagnosis and management of rare immune-related adverse events","volume":"25","author":"Schoenfeld","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.gastha.2026.100891_bib6","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2022-6-3","article-title":"Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review","volume":"11","author":"Schiepatti","year":"2022","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s40425-019-0694-x","article-title":"A case of checkpoint inhibitor-induced celiac disease","volume":"7","author":"Alsaadi","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"issue":"8","key":"10.1016\/j.gastha.2026.100891_bib8","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000158","article-title":"A celiac disease phenotype after checkpoint inhibitor exposure: an example of immune dysregulation after immunotherapy","volume":"6","author":"Arnouk","year":"2019","journal-title":"ACG Case Rep J"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gastha.2026.100891_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.871452","article-title":"Case report: fulminant celiac disease with combination immune checkpoint therapy","volume":"13","author":"Falade","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.gastha.2026.100891_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.mayocp.2013.01.015","article-title":"Association between ipilimumab and celiac disease","volume":"88","author":"Gentile","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gastha.2026.100891_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799666","article-title":"Celiac disease after administration of immune checkpoint inhibitors: a case report","volume":"12","author":"Leblanc","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.gastha.2026.100891_bib13","article-title":"Association of celiac disease with pembrolizumab","volume":"13","author":"Sethi","year":"2021","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.gastha.2026.100891_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-243406","article-title":"Immunotherapy-induced coeliac disease in curative lung cancer","volume":"14","author":"Walton","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12876-021-01936-w","article-title":"Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis","volume":"21","author":"Mu","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastha.2026.100891_bib16","doi-asserted-by":"crossref","first-page":"S914","DOI":"10.14309\/01.ajg.0000709124.47550.cd","article-title":"S1769 pertuzumab-induced enterocolitis: a novel entity?","volume":"115","author":"Parikh","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.gastha.2026.100891_bib17","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/ph15111365","article-title":"A review of the safety of interleukin-17A inhibitor secukinumab","volume":"15","author":"Eshwar","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.gastha.2026.100891_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fonc.2017.00168","article-title":"Rifaximin for pertuzumab-related GI toxicities","volume":"7","author":"Soyano","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.gastha.2026.100891_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.humpath.2015.12.001","article-title":"Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology","volume":"50","author":"Burbure","year":"2016","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.gastha.2026.100891_bib20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ajg.2013.45","article-title":"Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma","volume":"108","author":"DeGaetani","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.gastha.2026.100891_bib21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.12937","article-title":"Olmesartan-associated enteropathy: results of a national survey","volume":"40","author":"Marthey","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.gastha.2026.100891_bib22","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.mayocp.2012.06.003","article-title":"Severe spruelike enteropathy associated with olmesartan","volume":"87","author":"Rubio-Tapia","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.gastha.2026.100891_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.dld.2013.12.014","article-title":"Five cases of sprue-like enteropathy in patients treated by olmesartan","volume":"46","author":"Theophile","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.gastha.2026.100891_bib24","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00007890-199810270-00027","article-title":"Mycophenolate mofetil-induced villous atrophy","volume":"66","author":"Ducloux","year":"1998","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.gastha.2026.100891_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000812","article-title":"Celiac-like enteropathy associated with mycophenolate sodium in renal transplant recipients","volume":"4","author":"Filiopoulos","year":"2018","journal-title":"Transpl Direct"},{"issue":"5","key":"10.1016\/j.gastha.2026.100891_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.6002\/ect.2023.0034","article-title":"Celiac-like duodenopathy associated with enteric-coated mycophenolate sodium immunosuppression in renal transplant recipients: report of 4 cases","volume":"21","author":"Ivanovski","year":"2023","journal-title":"Exp Clin Transpl"},{"issue":"4","key":"10.1016\/j.gastha.2026.100891_bib27","first-page":"330","article-title":"Duodenal villous atrophy with a negative serology induced by mycophenolate mofetil: not everything is celiac disease","volume":"111","author":"Lucas Ramos","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastha.2026.100891_bib28","first-page":"192","article-title":"Mycophenolate induced diarrhoea","volume":"58","author":"Aiyangar","year":"2010","journal-title":"J Assoc Physicians India"},{"issue":"8","key":"10.1016\/j.gastha.2026.100891_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1432-2277.2004.tb00471.x","article-title":"Villous atrophy induced by mycophenolate mofetil in renal-transplant patients","volume":"17","author":"Kamar","year":"2004","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.gastha.2026.100891_bib30","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4067\/S0034-98872010000500010","volume":"138","author":"Tapia","year":"2010","journal-title":"Rev Med Chil"},{"issue":"9","key":"10.1016\/j.gastha.2026.100891_bib31","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/ccr3.2342","article-title":"Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: case report and review of the literature","volume":"7","author":"Duval","year":"2019","journal-title":"Clin Case Rep"},{"issue":"8","key":"10.1016\/j.gastha.2026.100891_bib32","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jtho.2019.12.119","article-title":"Coeliac-like disease is a rare immune-related complication induced by nivolumab in NSCLC","volume":"15","author":"Kokorian","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.gastha.2026.100891_bib33","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000882","article-title":"Open-capsule budesonide for the treatment of isolated immune checkpoint inhibitor-induced enteritis","volume":"9","author":"Hussain","year":"2022","journal-title":"ACG Case Rep J"},{"issue":"5","key":"10.1016\/j.gastha.2026.100891_bib34","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1016\/j.cllc.2018.04.013","article-title":"Widespread nivolumab-induced enteropathy in a long responder non-small-cell lung cancer patient","volume":"19","author":"Facchinetti","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.gastha.2026.100891_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CJI.0000000000000452","article-title":"Subclinical celiac disease unmasked by immune checkpoint inhibitor therapy","volume":"46","author":"Braun","year":"2023","journal-title":"J Immunother"},{"issue":"11","key":"10.1016\/j.gastha.2026.100891_bib36","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1080\/21645515.2018.1461297","article-title":"Immunotherapy in inflammatory bowel disease: novel and emerging treatments","volume":"14","author":"Catalan-Serra","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.gastha.2026.100891_bib37","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/ibd.21248","article-title":"IL-23\/IL-17 axis in IBD","volume":"16","author":"Sarra","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.gastha.2026.100891_bib38","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000260087","article-title":"Differential mucosal IL-17 expression in two gliadin-induced disorders: gluten sensitivity and the autoimmune enteropathy celiac disease","volume":"152","author":"Sapone","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.gastha.2026.100891_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2249.2011.04510.x","article-title":"Up-regulation of small intestinal interleukin-17 immunity in untreated coeliac disease but not in potential coeliac disease or in type 1 diabetes","volume":"167","author":"Lahdenper\u00e4","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.gastha.2026.100891_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.22551\/2022.37.0904.10227","article-title":"New onset severe ulcerative colitis following Ixekizumab therapy","volume":"9","author":"Morosanu","year":"2022","journal-title":"Arch Clin Cases"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/ejhpharm-2019-002016","article-title":"Ulcerative colitis induced by ixekizumab: a case report","volume":"28","author":"Marin","year":"2021","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"10.1016\/j.gastha.2026.100891_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-019-1380-z","article-title":"Celiac disease: a comprehensive current review","volume":"17","author":"Caio","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.gastha.2026.100891_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.947188","article-title":"The link between the microbiota and HER2+ breast cancer: the new challenge of precision medicine","volume":"12","author":"Di Modica","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.gastha.2026.100891_bib46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/biomedicines10030609","article-title":"Checkpoint inhibitors and induction of celiac disease-like condition","volume":"10","author":"Lerner","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.gastha.2026.100891_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","article-title":"Management of adverse events associated with cabozantinib therapy in renal cell carcinoma","volume":"23","author":"Schmidinger","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.gastha.2026.100891_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","article-title":"Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients","volume":"22","author":"Tolaney","year":"2017","journal-title":"Oncologist"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:12:29Z","timestamp":1775304749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326000129"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100891","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Celiac Disease After Immunotherapy: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"100891"}}